Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts give Gain Therapeutics a “Moderate Buy” consensus: Five of six analysts rate the stock a buy, while one rates it a sell. The average 12-month price target is $7.50, compared with a recent price of $1.83.
• Institutional investors and hedge funds own approximately 11.97% of the company, with several firms establishing new positions during the second and fourth quarters.
• Gain Therapeutics reported a quarterly loss of $0.11 per share, beating analyst expectations for a $0.14 loss. The clinical-stage biopharmaceutical company is developing GT-022 for Gaucher disease and other therapies for neurodegenerative and rare diseases.

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.50.

Several equities research analysts have recently commented on GANX shares. Weiss Ratings restated a "sell (e+)" rating on shares of Gain Therapeutics in a report on Friday. Roth Capital reiterated a "buy" rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Oppenheimer reissued an "outperform" rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. HC Wainwright restated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, August 31st. Finally, Wall Street Zen upgraded shares of Gain Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, June 21st.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Securities LLC acquired a new position in Gain Therapeutics during the 2nd quarter valued at about $26,000. HB Wealth Management LLC purchased a new stake in shares of Gain Therapeutics in the second quarter worth approximately $26,000. HighTower Advisors LLC bought a new position in shares of Gain Therapeutics in the second quarter valued at approximately $35,000. Sprott Inc. bought a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $39,000. Finally, Commonwealth Equity Services LLC bought a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $41,000. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Stock Performance

Shares of GANX opened at $1.83 on Wednesday. Gain Therapeutics has a one year low of $1.53 and a one year high of $4.34. The company has a market cap of $79.87 million, a PE ratio of -3.66 and a beta of 0.20. The stock has a 50-day moving average of $1.84 and a 200-day moving average of $1.94. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. On average, equities research analysts predict that Gain Therapeutics will post -0.5 EPS for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.